Polpharma Celebrates Being First With Natalizumab In Europe

Proposed Biosimilar Rival To Tysabri Begins EMA Review; Sandoz Has Marketing Rights

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.